Symbols / RANI $0.88 +4.41% Rani Therapeutics Holdings, Inc.
RANI Chart
About
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 87.44M |
| Enterprise Value | 46.86M | Income | -29.67M | Sales | 1.63M |
| Book/sh | 0.34 | Cash/sh | 0.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.28 | PEG | — |
| P/S | 53.54 | P/B | 2.59 | P/C | — |
| EV/EBITDA | -1.25 | EV/Sales | 28.69 | Quick Ratio | 4.08 |
| Current Ratio | 4.21 | Debt/Eq | 10.40 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.20 | EPS Growth | — |
| Revenue Growth | 42.10% | Earnings | 2026-05-13 | ROA | -50.27% |
| ROE | -181.98% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.84% | Profit Margin | 0.00% | Shs Outstand | 99.72M |
| Shs Float | 64.32M | Short Float | 10.91% | Short Ratio | 13.27 |
| Short Interest | — | 52W High | 3.87 | 52W Low | 0.39 |
| Beta | 0.66 | Avg Volume | 1.16M | Volume | 368.29K |
| Target Price | $7.00 | Recom | Strong_buy | Prev Close | $0.84 |
| Price | $0.88 | Change | 4.41% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-01 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2026-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-10-20 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-16 | main | Oppenheimer | Outperform → Outperform | $4 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-02-26 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-18 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-02 | init | Oppenheimer | — → Outperform | $17 |
| 2024-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-06-14 | init | Maxim Group | — → Buy | $15 |
| 2024-06-13 | init | Rodman & Renshaw | — → Buy | $10 |
| 2024-05-09 | main | BTIG | Buy → Buy | $14 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-03-27 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2024-03-25 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-06 | reit | Wedbush | Outperform → Outperform | $8 |
- RANI SEC Filings - Rani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan Mon, 16 Mar 2026 15
- Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st Sat, 31 Jan 2026 08
- RANI Apr 2026 2.000 put (RANI260410P00002000) Stock Price, News, Quote & History - Yahoo! Finance Canada Fri, 03 Apr 2026 11
- $RANI ($RANI) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Mar 2026 20
- Rani Therapeutics (RANI) Expected to Announce Earnings on Monday - MarketBeat Mon, 23 Mar 2026 07
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - GlobeNewswire hu, 26 Mar 2026 20
- If You Invested $1,000 in Rani Therapeutics Holdings, Inc. (RANI) - Stock Titan Sun, 22 Mar 2026 10
- RANI Apr 2026 0.500 put (RANI260417P00000500) Interactive Stock Chart - Yahoo! Finance Canada Fri, 03 Apr 2026 20
- $RANI stock is down 16% today. Here's what we see in our data. - Quiver Quantitative hu, 23 Oct 2025 07
- Rani turns to ex-Radius CEO Jesper Høiland to help pick pipeline bets - Stock Titan Wed, 25 Mar 2026 07
- RANI Apr 2026 1.500 put (RANI260402P00001500) Interactive Stock Chart - Yahoo! Finance Canada hu, 02 Apr 2026 19
- $RANI stock is up 13% today. Here's what we see in our data. | RANI Stock News - Quiver Quantitative Wed, 03 Dec 2025 08
- A pill instead of shots? Rani starts obesity study after $1.085B deal - Stock Titan hu, 26 Mar 2026 07
- Rani Therapeutics Holdings, Inc. Stock (RANI) Opinions on Billion-Dollar Chugai Deal | RANI Stock News - Quiver Quantitative hu, 23 Oct 2025 07
- Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings - Stock Titan Fri, 27 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.63
+58.85%
|
1.03
|
0.00
|
0.00
|
| Operating Revenue |
|
1.63
+58.85%
|
1.03
|
0.00
|
0.00
|
| Operating Expense |
|
39.94
-21.10%
|
50.63
-23.41%
|
66.10
+4.17%
|
63.45
|
| Research And Development |
|
20.20
-24.27%
|
26.68
-32.66%
|
39.62
+8.24%
|
36.61
|
| Selling General And Administration |
|
19.74
-17.57%
|
23.95
-9.55%
|
26.48
-1.37%
|
26.84
|
| General And Administrative Expense |
|
19.74
-17.57%
|
23.95
-9.55%
|
26.48
-1.37%
|
26.84
|
| Other Gand A |
|
19.74
-17.57%
|
23.95
-9.55%
|
26.48
-1.37%
|
26.84
|
| Total Expenses |
|
39.94
-21.10%
|
50.63
-23.41%
|
66.10
+4.17%
|
63.45
|
| Operating Income |
|
-38.31
+22.76%
|
-49.60
+24.96%
|
-66.10
-4.17%
|
-63.45
|
| Total Operating Income As Reported |
|
-38.31
+28.14%
|
-53.31
+19.34%
|
-66.10
-4.17%
|
-63.45
|
| EBITDA |
|
-37.16
+26.45%
|
-50.52
+18.48%
|
-61.98
-0.52%
|
-61.66
|
| Normalized EBITDA |
|
-36.58
+21.85%
|
-46.81
+24.47%
|
-61.98
-0.52%
|
-61.66
|
| Reconciled Depreciation |
|
0.90
-12.45%
|
1.03
+25.06%
|
0.82
+50.00%
|
0.55
|
| EBIT |
|
-38.06
+26.17%
|
-51.55
+17.91%
|
-62.80
-0.96%
|
-62.20
|
| Total Unusual Items |
|
-0.58
+84.49%
|
-3.71
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-0.58
+84.49%
|
-3.71
|
0.00
|
0.00
|
| Special Income Charges |
|
-0.58
+84.49%
|
-3.71
|
0.00
|
0.00
|
| Other Special Charges |
|
0.58
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
3.71
|
0.00
|
—
|
| Write Off |
|
0.00
-100.00%
|
3.71
|
0.00
|
—
|
| Net Income |
|
-29.67
+1.15%
|
-30.02
+11.63%
|
-33.97
-11.06%
|
-30.59
|
| Pretax Income |
|
-40.95
+27.63%
|
-56.58
+16.64%
|
-67.88
-7.28%
|
-63.27
|
| Net Non Operating Interest Income Expense |
|
-2.06
+36.88%
|
-3.27
-83.30%
|
-1.78
-1107.91%
|
0.18
|
| Interest Expense Non Operating |
|
2.89
-42.56%
|
5.03
-1.02%
|
5.08
+374.79%
|
1.07
|
| Net Interest Income |
|
-2.06
+36.88%
|
-3.27
-83.30%
|
-1.78
-1107.91%
|
0.18
|
| Interest Expense |
|
2.89
-42.56%
|
5.03
-1.02%
|
5.08
+374.79%
|
1.07
|
| Interest Income Non Operating |
|
0.83
-53.09%
|
1.76
-46.59%
|
3.30
+164.50%
|
1.25
|
| Interest Income |
|
0.83
-53.09%
|
1.76
-46.59%
|
3.30
+164.50%
|
1.25
|
| Other Income Expense |
|
-0.58
+84.49%
|
-3.71
|
—
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-40.95
+27.63%
|
-56.58
+16.64%
|
-67.88
-7.17%
|
-63.34
|
| Net Income From Continuing Operation Net Minority Interest |
|
-29.67
+1.15%
|
-30.02
+11.63%
|
-33.97
-11.06%
|
-30.59
|
| Net Income From Continuing And Discontinued Operation |
|
-29.67
+1.15%
|
-30.02
+11.63%
|
-33.97
-11.06%
|
-30.59
|
| Net Income Continuous Operations |
|
-40.95
+27.63%
|
-56.58
+16.64%
|
-67.88
-7.17%
|
-63.34
|
| Minority Interests |
|
11.28
-57.55%
|
26.57
-21.66%
|
33.91
+3.53%
|
32.76
|
| Normalized Income |
|
-29.10
-10.62%
|
-26.30
+22.57%
|
-33.97
-11.06%
|
-30.59
|
| Net Income Common Stockholders |
|
-29.67
+1.15%
|
-30.02
+11.63%
|
-33.97
-11.06%
|
-30.59
|
| Diluted EPS |
|
—
|
-1.05
+21.05%
|
-1.33
-3.91%
|
-1.28
|
| Basic EPS |
|
—
|
-1.05
+21.05%
|
-1.33
-3.91%
|
-1.28
|
| Basic Average Shares |
|
—
|
28.48
+11.65%
|
25.50
+7.09%
|
23.82
|
| Diluted Average Shares |
|
—
|
28.48
+11.65%
|
25.50
+7.09%
|
23.82
|
| Diluted NI Availto Com Stockholders |
|
-29.67
+1.15%
|
-30.02
+11.63%
|
-33.97
-11.06%
|
-30.59
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
58.62
+60.02%
|
36.63
-36.75%
|
57.92
-46.39%
|
108.03
|
| Current Assets |
|
53.32
+79.27%
|
29.74
-41.50%
|
50.85
-49.62%
|
100.92
|
| Cash Cash Equivalents And Short Term Investments |
|
49.71
+79.85%
|
27.64
-43.06%
|
48.54
-50.71%
|
98.48
|
| Cash And Cash Equivalents |
|
18.62
+394.90%
|
3.76
-35.85%
|
5.86
-78.29%
|
27.01
|
| Other Short Term Investments |
|
31.09
+30.21%
|
23.88
-44.05%
|
42.67
-40.29%
|
71.47
|
| Receivables |
|
2.04
+377.10%
|
0.43
|
0.00
|
—
|
| Accounts Receivable |
|
2.04
|
0.00
|
—
|
—
|
| Other Receivables |
|
—
|
0.43
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
—
|
—
|
—
|
0.50
|
| Other Current Assets |
|
1.57
-6.38%
|
1.68
-27.34%
|
2.31
-5.49%
|
2.44
|
| Total Non Current Assets |
|
5.30
-23.08%
|
6.89
-2.53%
|
7.07
-0.48%
|
7.10
|
| Net PPE |
|
5.05
-23.93%
|
6.64
-2.62%
|
6.82
-3.94%
|
7.10
|
| Gross PPE |
|
10.59
-6.11%
|
11.28
+7.53%
|
10.49
+5.45%
|
9.95
|
| Accumulated Depreciation |
|
-5.54
-19.40%
|
-4.64
-26.40%
|
-3.67
-28.85%
|
-2.85
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.33
+23.05%
|
0.27
+3.07%
|
0.26
+0.00%
|
0.26
|
| Construction In Progress |
|
0.03
+0.00%
|
0.03
-99.21%
|
3.90
-11.59%
|
4.42
|
| Other Properties |
|
8.58
-8.06%
|
9.33
+96.77%
|
4.74
+27.24%
|
3.73
|
| Leases |
|
1.66
+0.00%
|
1.66
+4.22%
|
1.59
+2.52%
|
1.55
|
| Other Non Current Assets |
|
0.25
+0.00%
|
0.25
+0.00%
|
0.25
|
—
|
| Total Liabilities Net Minority Interest |
|
17.11
-48.38%
|
33.14
+2.06%
|
32.47
-4.56%
|
34.02
|
| Current Liabilities |
|
12.67
-36.31%
|
19.89
+148.98%
|
7.99
+65.92%
|
4.82
|
| Payables And Accrued Expenses |
|
4.21
+33.57%
|
3.15
+48.54%
|
2.12
-35.19%
|
3.27
|
| Payables |
|
0.31
-77.26%
|
1.36
+109.72%
|
0.65
-57.17%
|
1.51
|
| Accounts Payable |
|
0.31
-77.26%
|
1.36
+109.72%
|
0.65
-55.62%
|
1.46
|
| Current Accrued Expenses |
|
3.90
+117.71%
|
1.79
+21.60%
|
1.47
-16.27%
|
1.76
|
| Current Debt And Capital Lease Obligation |
|
1.59
-90.36%
|
16.46
+193.13%
|
5.62
+458.15%
|
1.01
|
| Current Debt |
|
—
|
15.00
+206.31%
|
4.90
|
—
|
| Other Current Borrowings |
|
—
|
15.00
+206.31%
|
4.90
|
—
|
| Current Capital Lease Obligation |
|
1.59
+8.70%
|
1.46
+103.20%
|
0.72
-28.63%
|
1.01
|
| Current Deferred Liabilities |
|
6.83
|
0.00
|
—
|
—
|
| Current Deferred Revenue |
|
6.83
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
0.05
-83.75%
|
0.28
+11.42%
|
0.25
-52.79%
|
0.54
|
| Total Non Current Liabilities Net Minority Interest |
|
4.44
-66.49%
|
13.25
-45.88%
|
24.48
-16.17%
|
29.21
|
| Long Term Debt And Capital Lease Obligation |
|
2.73
-79.38%
|
13.25
-45.88%
|
24.48
-16.17%
|
29.21
|
| Long Term Debt |
|
—
|
9.61
-60.74%
|
24.48
-16.00%
|
29.15
|
| Long Term Capital Lease Obligation |
|
2.73
-24.88%
|
3.64
|
0.00
-100.00%
|
0.06
|
| Non Current Deferred Liabilities |
|
1.71
|
0.00
|
—
|
—
|
| Non Current Deferred Revenue |
|
1.71
|
0.00
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
33.01
+1557.13%
|
1.99
-84.52%
|
12.87
-65.09%
|
36.85
|
| Common Stock Equity |
|
33.01
+1557.13%
|
1.99
-84.52%
|
12.87
-65.09%
|
36.85
|
| Capital Stock |
|
0.01
+120.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+120.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
97.62
+192.02%
|
33.43
+28.40%
|
26.04
+2.93%
|
25.30
|
| Ordinary Shares Number |
|
97.62
+192.02%
|
33.43
+28.40%
|
26.04
+2.93%
|
25.30
|
| Additional Paid In Capital |
|
165.58
+57.86%
|
104.89
+22.30%
|
85.76
+13.08%
|
75.84
|
| Retained Earnings |
|
-132.58
-28.83%
|
-102.91
-41.18%
|
-72.89
-87.28%
|
-38.92
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
-80.00%
|
0.01
+141.67%
|
-0.01
+83.56%
|
-0.07
|
| Minority Interest |
|
8.50
+466.42%
|
1.50
-88.07%
|
12.58
-66.14%
|
37.15
|
| Total Equity Gross Minority Interest |
|
41.51
+1088.43%
|
3.49
-86.27%
|
25.44
-65.62%
|
74.00
|
| Total Capitalization |
|
33.01
+184.45%
|
11.61
-68.93%
|
37.35
-43.41%
|
66.00
|
| Working Capital |
|
40.65
+312.58%
|
9.85
-77.01%
|
42.86
-55.41%
|
96.11
|
| Invested Capital |
|
33.01
+24.07%
|
26.61
-37.03%
|
42.25
-35.99%
|
66.00
|
| Total Debt |
|
4.32
-85.47%
|
29.71
-1.30%
|
30.10
-0.38%
|
30.21
|
| Net Debt |
|
—
|
20.85
-11.34%
|
23.52
+997.90%
|
2.14
|
| Capital Lease Obligations |
|
4.32
-15.27%
|
5.10
+609.75%
|
0.72
-32.58%
|
1.06
|
| Net Tangible Assets |
|
33.01
+1557.13%
|
1.99
-84.52%
|
12.87
-65.09%
|
36.85
|
| Tangible Book Value |
|
33.01
+1557.13%
|
1.99
-84.52%
|
12.87
-65.09%
|
36.85
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
—
|
| Dueto Related Parties Current |
|
—
|
—
|
0.05
-1.89%
|
0.05
|
| Interest Payable |
|
0.00
-100.00%
|
0.93
+86.20%
|
0.50
+624.64%
|
0.07
|
| Notes Receivable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-18.71
+47.28%
|
-35.50
+30.72%
|
-51.24
-10.15%
|
-46.52
|
| Cash Flow From Continuing Operating Activities |
|
-18.71
+47.28%
|
-35.50
+30.72%
|
-51.24
-10.15%
|
-46.52
|
| Net Income From Continuing Operations |
|
-40.95
+27.63%
|
-56.58
+16.64%
|
-67.88
-7.17%
|
-63.34
|
| Depreciation Amortization Depletion |
|
0.90
-12.45%
|
1.03
+25.06%
|
0.82
+50.00%
|
0.55
|
| Depreciation |
|
—
|
—
|
0.80
+60.00%
|
0.50
|
| Depreciation And Amortization |
|
0.90
-12.45%
|
1.03
+25.06%
|
0.82
+50.00%
|
0.55
|
| Other Non Cash Items |
|
2.12
+3.63%
|
2.04
+60.33%
|
1.27
+51.37%
|
0.84
|
| Stock Based Compensation |
|
11.80
-26.41%
|
16.03
-15.66%
|
19.01
+20.44%
|
15.78
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
3.71
|
0.00
|
—
|
| Operating Gains Losses |
|
0.74
+1043.08%
|
0.07
|
—
|
—
|
| Gain Loss On Investment Securities |
|
0.17
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.07
|
0.00
|
—
|
| Change In Working Capital |
|
6.96
+1379.04%
|
-0.54
+74.58%
|
-2.14
-520.43%
|
0.51
|
| Change In Receivables |
|
-1.61
-277.10%
|
-0.43
|
0.00
|
—
|
| Changes In Account Receivables |
|
-2.04
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
-0.19
-130.43%
|
0.63
+123.76%
|
0.28
-44.16%
|
0.51
|
| Change In Payables And Accrued Expense |
|
2.13
+101.13%
|
1.06
+193.48%
|
-1.14
-247.79%
|
0.77
|
| Change In Accrued Expense |
|
3.18
+809.71%
|
0.35
+164.81%
|
-0.54
-189.26%
|
0.60
|
| Change In Payable |
|
-1.05
-247.68%
|
0.71
+219.50%
|
-0.59
-465.03%
|
0.16
|
| Change In Account Payable |
|
-1.05
-247.68%
|
0.71
+219.50%
|
-0.59
-465.03%
|
0.16
|
| Change In Other Working Capital |
|
8.54
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
—
|
0.00
+100.00%
|
-0.24
|
0.00
|
| Change In Other Current Liabilities |
|
-1.91
-5.59%
|
-1.81
-73.51%
|
-1.04
-36.39%
|
-0.76
|
| Investing Cash Flow |
|
-7.03
-135.49%
|
19.81
-33.66%
|
29.86
+141.22%
|
-72.44
|
| Cash Flow From Continuing Investing Activities |
|
-7.03
-135.49%
|
19.81
-33.66%
|
29.86
+141.22%
|
-72.44
|
| Net PPE Purchase And Sale |
|
-0.09
+67.16%
|
-0.27
+78.19%
|
-1.23
+24.09%
|
-1.62
|
| Purchase Of PPE |
|
-0.09
+67.16%
|
-0.27
+78.19%
|
-1.23
+24.09%
|
-1.62
|
| Capital Expenditure |
|
-0.09
+67.16%
|
-0.27
+78.19%
|
-1.23
+24.09%
|
-1.62
|
| Net Investment Purchase And Sale |
|
-6.94
-134.58%
|
20.08
-35.42%
|
31.09
+143.90%
|
-70.82
|
| Purchase Of Investment |
|
-33.69
+41.38%
|
-57.47
+21.55%
|
-73.26
+0.75%
|
-73.82
|
| Sale Of Investment |
|
26.75
-65.51%
|
77.55
-25.68%
|
104.35
+3378.33%
|
3.00
|
| Financing Cash Flow |
|
40.30
+196.65%
|
13.59
+5730.47%
|
0.23
-99.20%
|
29.00
|
| Cash Flow From Continuing Financing Activities |
|
40.30
+196.65%
|
13.59
+5730.47%
|
0.23
-99.20%
|
29.00
|
| Net Issuance Payments Of Debt |
|
-20.72
-314.44%
|
-5.00
|
0.00
-100.00%
|
29.57
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
29.57
|
| Repayment Of Debt |
|
-20.72
-314.44%
|
-5.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
29.57
|
| Long Term Debt Payments |
|
-20.72
-314.44%
|
-5.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
-20.72
-314.44%
|
-5.00
|
0.00
-100.00%
|
29.57
|
| Net Common Stock Issuance |
|
52.60
+188.02%
|
18.26
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
8.48
+2192.43%
|
0.37
-6.33%
|
0.40
+24.61%
|
0.32
|
| Net Other Financing Charges |
|
-0.06
-25.53%
|
-0.05
+70.99%
|
-0.16
+81.72%
|
-0.89
|
| Changes In Cash |
|
14.56
+792.48%
|
-2.10
+90.06%
|
-21.14
+76.49%
|
-89.95
|
| Beginning Cash Position |
|
4.26
-33.03%
|
6.36
-76.86%
|
27.51
-76.58%
|
117.45
|
| End Cash Position |
|
18.82
+341.53%
|
4.26
-33.03%
|
6.36
-76.86%
|
27.51
|
| Free Cash Flow |
|
-18.80
+47.43%
|
-35.76
+31.83%
|
-52.47
-9.00%
|
-48.13
|
| Interest Paid Supplemental Data |
|
2.12
-48.42%
|
4.11
-1.67%
|
4.18
+472.88%
|
0.73
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.04
-27.08%
|
0.05
|
| Amortization Of Securities |
|
-0.28
+77.71%
|
-1.25
+46.16%
|
-2.32
-172.15%
|
-0.85
|
| Common Stock Issuance |
|
52.60
+188.02%
|
18.26
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
52.60
+188.02%
|
18.26
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 8-K2026-01-02 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 42025-10-30 View
- 42025-10-27 View
- 42025-10-27 View
- 8-K2025-10-27 View
- 42025-10-22 View
- 8-K2025-10-17 View
- 10-Q2025-08-07 View
- 8-K2025-08-07 View
- 42025-08-05 View
- 8-K2025-07-16 View
- 8-K2025-06-26 View
- 42025-05-30 View
- 42025-05-30 View
- 42025-05-30 View
- 42025-05-30 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|